PDL BioPharma to Hold Annual Meeting of Stockholders on June 8, 2018
PDL seeks to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. In 2012, PDL began providing alternative sources of capital through royalty monetizations and debt facilities, and in 2016, the Company began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. To date, PDL has consummated 17 of such transactions, of which nine are active and outstanding. The Company has one debt transaction outstanding, representing deployed and committed capital of
The Company operates in three segments designated as Income Generating Assets, Pharmaceutical and Medical Devices.
View original content with multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-to-hold-annual-meeting-of-stockholders-on-june-8-2018-300630005.html
Peter Garcia, PDL BioPharma, Inc., 775-832-8500, firstname.lastname@example.org; Jennifer Williams, Cook Williams Communications, Inc., 360-668-3701, email@example.com